Cubist Systematic Strategies LLC Acquires 88,175 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Cubist Systematic Strategies LLC boosted its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 1,350.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 94,705 shares of the company’s stock after purchasing an additional 88,175 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.07% of Organogenesis worth $265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ORGO. Assenagon Asset Management S.A. increased its position in Organogenesis by 309.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after buying an additional 3,005,450 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after acquiring an additional 986,132 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Organogenesis in the 1st quarter worth about $1,846,000. Acadian Asset Management LLC boosted its stake in Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock worth $8,521,000 after purchasing an additional 471,741 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Organogenesis by 19.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after purchasing an additional 333,123 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.

Organogenesis Stock Up 0.7 %

Shares of Organogenesis stock opened at $3.09 on Tuesday. The company has a market cap of $409.65 million, a price-to-earnings ratio of 77.25 and a beta of 1.60. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $2.78 and its 200 day moving average is $2.76. Organogenesis Holdings Inc. has a twelve month low of $1.96 and a twelve month high of $4.70.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The firm had revenue of $130.23 million during the quarter, compared to analysts’ expectations of $122.48 million. Research analysts anticipate that Organogenesis Holdings Inc. will post -0.19 EPS for the current year.

Analysts Set New Price Targets

Separately, Lake Street Capital began coverage on shares of Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price for the company.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.